217 related articles for article (PubMed ID: 34548567)
1. Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions.
Morita C; Yoshida T; Shirasawa M; Masuda K; Matsumoto Y; Shinno Y; Yagishita S; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Motoi N; Yatabe Y; Ohe Y
Sci Rep; 2021 Sep; 11(1):18762. PubMed ID: 34548567
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia.
Okahisa M; Udagawa H; Matsumoto S; Kato T; Yokouchi H; Furuya N; Kanemaru R; Toyozawa R; Nishiyama A; Ohashi K; Miyamoto S; Nishino K; Nakamura A; Iwama E; Niho S; Oi H; Sakai T; Shibata Y; Izumi H; Sugiyama E; Nosaki K; Umemura S; Zenke Y; Yoh K; Kah Mun Low G; Zhuo J; Goto K
Lung Cancer; 2024 May; 191():107798. PubMed ID: 38669727
[TBL] [Abstract][Full Text] [Related]
3. EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer.
Leal JL; Alexander M; Itchins M; Wright GM; Kao S; Hughes BGM; Pavlakis N; Clarke S; Gill AJ; Ainsworth H; Solomon B; John T
Clin Lung Cancer; 2021 Nov; 22(6):e859-e869. PubMed ID: 34127383
[TBL] [Abstract][Full Text] [Related]
4. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations.
Bazhenova L; Minchom A; Viteri S; Bauml JM; Ou SI; Gadgeel SM; Trigo JM; Backenroth D; Li T; Londhe A; Mahadevia P; Girard N
Lung Cancer; 2021 Dec; 162():154-161. PubMed ID: 34818606
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib.
Naidoo J; Sima CS; Rodriguez K; Busby N; Nafa K; Ladanyi M; Riely GJ; Kris MG; Arcila ME; Yu HA
Cancer; 2015 Sep; 121(18):3212-3220. PubMed ID: 26096453
[TBL] [Abstract][Full Text] [Related]
6. Prevalence, Treatment Patterns, and Outcomes of Individuals with
O'Sullivan DE; Jarada TN; Yusuf A; Hu LXY; Gogna P; Brenner DR; Abbie E; Rose JB; Eaton K; Elia-Pacitti J; Ewara EM; Pabani A; Cheung WY; Boyne DJ
Curr Oncol; 2022 Sep; 29(10):7198-7208. PubMed ID: 36290844
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations.
Wu JY; Yu CJ; Shih JY
Clin Lung Cancer; 2019 Nov; 20(6):e620-e630. PubMed ID: 31327643
[TBL] [Abstract][Full Text] [Related]
8. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
Park K; Haura EB; Leighl NB; Mitchell P; Shu CA; Girard N; Viteri S; Han JY; Kim SW; Lee CK; Sabari JK; Spira AI; Yang TY; Kim DW; Lee KH; Sanborn RE; Trigo J; Goto K; Lee JS; Yang JC; Govindan R; Bauml JM; Garrido P; Krebs MG; Reckamp KL; Xie J; Curtin JC; Haddish-Berhane N; Roshak A; Millington D; Lorenzini P; Thayu M; Knoblauch RE; Cho BC
J Clin Oncol; 2021 Oct; 39(30):3391-3402. PubMed ID: 34339292
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea.
Byeon S; Kim Y; Lim SW; Cho JH; Park S; Lee J; Sun JM; Choi YL; Lee SH; Ahn JS; Park K; Ahn MJ
Cancer Res Treat; 2019 Apr; 51(2):623-631. PubMed ID: 30049203
[TBL] [Abstract][Full Text] [Related]
10. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.
Oxnard GR; Lo PC; Nishino M; Dahlberg SE; Lindeman NI; Butaney M; Jackman DM; Johnson BE; Jänne PA
J Thorac Oncol; 2013 Feb; 8(2):179-84. PubMed ID: 23328547
[TBL] [Abstract][Full Text] [Related]
11. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.
Prelaj A; Bottiglieri A; Proto C; Lo Russo G; Signorelli D; Ferrara R; Galli G; De Toma A; Viscardi G; Brambilla M; Lobefaro R; Nichetti F; Manglaviti S; Occhipinti M; Labianca A; Ganzinelli M; Gallucci R; Zilembo N; Greco GF; Torri V; de Braud F; Garassino MC
Eur J Cancer; 2021 May; 149():235-248. PubMed ID: 33820681
[TBL] [Abstract][Full Text] [Related]
12. The development of amivantamab for the treatment of non-small cell lung cancer.
Brazel D; Nagasaka M
Respir Res; 2023 Oct; 24(1):256. PubMed ID: 37880647
[TBL] [Abstract][Full Text] [Related]
13. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
14. Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options.
Brazel D; Kroening G; Nagasaka M
BioDrugs; 2022 Nov; 36(6):717-729. PubMed ID: 36255589
[TBL] [Abstract][Full Text] [Related]
15. An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.
Chouaid C; Bosquet L; Girard N; Kron A; Scheffler M; Griesinger F; Sebastian M; Trigo J; Viteri S; Knott C; Rodrigues B; Rahhali N; Cabrieto J; Diels J; Perualila NJ; Schioppa CA; Sermon J; Toueg R; Erdmann N; Mielke J; Nematian-Samani M; Martin-Fernandez C; Pfaira I; Li T; Mahadevia P; Wolf J
Adv Ther; 2023 Mar; 40(3):1187-1203. PubMed ID: 36652175
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of
Skrickova J; Pesek M; Opalka P; Koubkova L; Zemanova M; Hrnciarik M; Blazek J; Svaton M; Krejci J; Coupkova H; Dolezal D; Tuzova T; Holubec L; Mahadevia P; Sandstrom K; Kunovszki P; Barinova M; Hurdalkova K; Fischer O; Cernovska M; Bratova M
Anticancer Res; 2021 Nov; 41(11):5625-5634. PubMed ID: 34732435
[TBL] [Abstract][Full Text] [Related]
17. Multinational proficiency tests for EGFR exon 20 insertions reveal that the assay design matters.
Ihle MA; Heydt C; Schultheis AM; Stöhr R; Haller F; Herold S; Aust D; Dietmaier W; Evert M; Eszlinger M; Haak A; Laßmann S; Vorholt D; Breitenbücher F; Werner M; Streubel A; Mairinger T; Grassow-Narlik M; Merkelbach-Bruse S
Sci Rep; 2024 Jun; 14(1):13069. PubMed ID: 38844820
[TBL] [Abstract][Full Text] [Related]
18. [Characteristics of Epidermal Growth Factor Receptor with Rare Mutations in Non-small Cell Lung Cancer and the Effect of EGFR Tyrosine Kinase Inhibitors on Them].
Shi Y; Li P; Li B; Zhang F; Huang S; Shen S; Li X
Zhongguo Fei Ai Za Zhi; 2019 May; 22(5):299-305. PubMed ID: 31109439
[TBL] [Abstract][Full Text] [Related]
19. EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non-Small Cell Lung Cancer Patients.
Choi YW; Jeon SY; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Koh YW; Han JH; Sheen SS
Am J Clin Oncol; 2018 Apr; 41(4):385-390. PubMed ID: 26967328
[TBL] [Abstract][Full Text] [Related]
20. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of
Yun J; Lee SH; Kim SY; Jeong SY; Kim JH; Pyo KH; Park CW; Heo SG; Yun MR; Lim S; Lim SM; Hong MH; Kim HR; Thayu M; Curtin JC; Knoblauch RE; Lorenzi MV; Roshak A; Cho BC
Cancer Discov; 2020 Aug; 10(8):1194-1209. PubMed ID: 32414908
[No Abstract] [Full Text] [Related]
[Next] [New Search]
